Details for New Drug Application (NDA): 202360
✉ Email this page to a colleague
NDA 202360 describes ETOMIDATE, which is a drug marketed by Avet Lifesciences, Caplin, Endo Operations, Eugia Pharma, Gland Pharma Ltd, Hikma, Luitpold, Mylan Labs Ltd, Rising, and Zydus Pharms, and is included in eleven NDAs. It is available from twelve suppliers. Additional details are available on the ETOMIDATE profile page.
The generic ingredient in ETOMIDATE is etomidate. There are six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the etomidate profile page.
The generic ingredient in ETOMIDATE is etomidate. There are six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the etomidate profile page.
Summary for 202360
| Tradename: | ETOMIDATE |
| Applicant: | Zydus Pharms |
| Ingredient: | etomidate |
| Patents: | 0 |
Pharmacology for NDA: 202360
| Physiological Effect | General Anesthesia |
Medical Subject Heading (MeSH) Categories for 202360
Suppliers and Packaging for NDA: 202360
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ETOMIDATE | etomidate | INJECTABLE;INJECTION | 202360 | ANDA | Zydus Lifesciences Limited | 65841-818 | 65841-818-07 | 10 VIAL in 1 TRAY (65841-818-07) / 10 mL in 1 VIAL |
| ETOMIDATE | etomidate | INJECTABLE;INJECTION | 202360 | ANDA | Zydus Lifesciences Limited | 65841-818 | 65841-818-08 | 10 VIAL in 1 TRAY (65841-818-08) / 20 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 2MG/ML | ||||
| Approval Date: | Jul 18, 2014 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
